TOlerance MOlecular and Genome-wide Studies With Renal Allograft Recipient Material

Conditions

Kidney Transplantation

Brief summary

TOMOGRAM is a European multicentric, prospective, experimental, controlled study that aims to increase our understanding of the causative mechanisms of operational tolerance in kidney transplantation through the achievement of several multimodal whole-genomic analysis in human biological samples.

Hruba P, Klema J, Le AV, Girmanova E, Mrazova P, Massart A, Maixnerova D, Voska L, Piredda GB, Biancone L, Puga AR, Seyahi N, Sever MS, Weekers L, Muhfeld A, Budde K, Watschinger B, Miglinas M, Zahradka I, Abramowicz M, Abramowicz D, Viklicky O.

2023-09-014 citations

10.1016/j.ebiom.2023.104782

#4917 AN EXOME-WIDE STUDY OF RENAL OPERATIONAL TOLERANCE

Annick Massart, Richard Danger, Catharina Olsen, Mary J. Emond, Ondřej Viklický et al. (22 authors)

Nephrology Dialysis Transplantation2023-06-01

10.1093/ndt/gfad063b_4917

An exome-wide study of renal operational tolerance

Annick Massart, Richard Danger, Catharina Olsen, Mary J. Emond, Ondřej Viklický et al. (24 authors)

Frontiers in Medicine2023-05-173 citations

10.3389/fmed.2022.976248

Interventions

GENETICHigh throughput DNA and RNA sequencing

High throughput DNA and RNA sequencing

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Intervention model description

1. Exome-wide association study 2. Transcriptomic analyses

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* recipient of an allogenic renal allograft, * have experienced (whatever ongoing or not) at least a whole year with blood creatinine \<1.7 mg/dL and proteinuria \</=1g/day or /g creatinine despite the COMPLETE discontinuation of immunosuppressive drugs, * alternatively, have experienced (whatever ongoing or not) at least a whole year with stable blood creatinine (max 20% variation) and proteinuria above these criteria despite the COMPLETE discontinuation of immunosuppressive drugs

Exclusion criteria

* Past medical history of allogeneic bone-marrow transplantation / combined organ transplantation

Design outcomes

Primary

Measure	Time frame
Number of moderately to highly damaging exonic variants	Through study completion, an average of 2 year

Outcome results

None listed